Case No.: 21573YP Page No.: 2

## **Amendments to the Claims:**

The listing of claims will replace all prior versions, and listings, of claims in the application:

## **Listing of Claims**

1. (Currently Amended) A compound of the formula I:

I

wherein:

R1 is selected from one or more of the groups consisting of:

- (1) hydrogen,
- (2) C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy or phenyl,
- (3) -O-C<sub>1</sub>-6alkyl,
- (4) halogen,
- (5) phenyl, which is substituted with R2a, R2b and R2c,
- (6) heterocycle, which is substituted with R2a, R2b and R2c,
- (7) -CN,
- (8)  $-CO_2R^9$ ,

wherein R<sup>9</sup> is independently selected from:

- (a) hydrogen,
- (b) -C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with 1-6 fluoro,
- (c) benzyl, and
- (d) phenyl,

Case No.: 21573YP Page No.: 3

(9)  $-SO_2R^9$ ,

(10) -SO<sub>2</sub>-NR<sup>10</sup>R<sup>11</sup>,

wherein  $R^{10}$  and  $R^{11}$  are independently selected from:

- (a) hydrogen,
- (b) -C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with hydroxy, 1-6 fluoro or -NR<sup>12</sup>R<sup>13</sup>, where R<sup>12</sup> and R<sup>13</sup> are independently selected from hydrogen and -C<sub>1-6</sub>alkyl, and where R<sup>10</sup> and R<sup>11</sup> may be joined to form an azetidinyl ring,
- -C3-6cycloalkyl, which is unsubstituted or substituted with hydroxy, 1-6 fluoro or -NR12R13.
- (d) benzyl,
- (e) phenyl, and
- (11)  $-CONR^{10}R^{11}$ ;

R<sup>2</sup> is selected from the group consisting of:

- (1) phenyl, which is substituted with R<sup>2</sup>a, R<sup>2</sup>b and R<sup>2</sup>c,
- (2) heterocycle, which is substituted with R2a, R2b and R2c,
- (3) C<sub>1-8</sub>alkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy,
- -NR<sup>10</sup>R<sup>11</sup>, phenyl or heterocycle, where the phenyl or heterocycle is substituted with R<sup>2a</sup>, R<sup>2b</sup> and R<sup>2e</sup>, and
- (3)(4) C<sub>3</sub>-6cycloalkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy or NR10R11, and
- (5) -C<sub>1-6</sub>alkyl-(C<sub>3-6</sub>cycloalkyl), which is unsubstituted or substituted with 1-6 halogen, hydroxy or -NR<sup>10</sup>R<sup>11</sup>;

R<sup>2</sup>a, R<sup>2</sup>b and R<sup>2</sup>c are independently selected from the group consisting of:

- (1) hydrogen,
- (2) halogen,
- (3) -C<sub>1</sub>-6alkyl, which is unsubstituted or substituted with:
  - (a) 1-6 halogen,
  - (b) phenyl,

Case No.: 21573YP

Page No.: 4

- (c) C3-6cycloalkyl, or
- (d)  $-NR^{10}R^{11}$ ,
- (4) -O-C<sub>1</sub>-6alkyl, which is <del>unsubstituted or</del> substituted with 1-6 halogen,
- (5) hydroxy,
- (6) -SCF<sub>3</sub>,
- (7) -SCHF<sub>2</sub>,
- (8) -SCH<sub>3</sub>,
- (9)  $-CO_2R^9$ ,
- (10) -CN,
- (11)  $-SO_2R^9$ ,
- (12) -SO<sub>2</sub>-NR<sup>10</sup>R<sup>11</sup>,
- (13) -NR10R11,
- (14) -CONR<sup>10</sup>R<sup>11</sup>, and
- (15) -NO<sub>2</sub>;

## R<sup>3</sup> is selected from the group consisting of:

- (1) C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxyl, -NR<sup>10</sup>R<sup>11</sup>, or heterocycle, which is substituted with R<sup>2</sup>a, R<sup>2</sup>b and R<sup>2</sup>c,
- (2) C<sub>3</sub> 6cycloalkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxyl or NR10R11.
- (3) -C<sub>1-6</sub>alkyl-(C<sub>3-6</sub>eycloalkyl), which is unsubstituted or substituted with 1-6 halogen, hydroxy or -NR<sup>10</sup>R<sup>11</sup>, and
- (4) NR<sup>10</sup>R<sup>11</sup>, and
- (5) heterocycle, which is substituted with R<sup>2a</sup>, R<sup>2b</sup> and R<sup>2c</sup>;

R4 and R5 are independently selected from the group consisting of:

- (1) hydrogen, and
- (2) C<sub>1-6</sub>alkyl, which is unsubstituted or substituted with halogen or hydroxyl,

or R<sup>4</sup> and R<sup>5</sup> taken together form a C<sub>3</sub>-6cycloalkyl ring;

Case No.: 21573YP Page No.: 5

Tugo I Vo

(1) 1 1 1

(1) hydrogen, and

R<sup>6</sup> is selected from the group consisting of:

- (2) C<sub>1-6</sub>alkyl;
- W, X, Y and Z are independently selected from C or N, with the proviso that at least two of W, X, Y and Z are C, to form a pyridine, oxo-dihydropyridine, pyridazine, pyrimidine, pyrazine, 1,2,4-triazine or 1,3,5-triazine ring;

A is selected from the group consisting of:

- (1) -O-, and
- (2) -NR10-:

m is zero or one, whereby when m is zero R<sup>2</sup> is attached directly to the carbonyl; and pharmaceutically acceptable salts thereof.

2. (original) The compound of Claim 1 of the formula Ia:

$$\begin{array}{c|cccc}
R^1 & R^4 & R^5 & O \\
N & N & N & R^2 \\
N & N & N & N & R^2 \\
O = S = O & R^3
\end{array}$$

Ia

or a pharmaceutically acceptable salt thereof.

- 3. (original) The compound of Claim 1 wherein  $\mathbb{R}^1$  is selected from the group consisting of:
  - (1) hydrogen,
  - (2) C<sub>1-3</sub>alkyl,
  - (3) fluoro,
  - (4) -CF<sub>3</sub>,

Case No.: 21573YP Page No.: 6

- (5) -morpholinyl, and
- (6) -O-C<sub>1</sub>-3alkyl.
  - 4. (Original) The compound of Claim 3 wherein R<sup>1</sup> is hydrogen or methyl.
  - 5. (Original) The compound of Claim 1 of the formula Ib:

$$R^{1} \xrightarrow{N} N \xrightarrow{R^{2}} N \xrightarrow{R^{2}} N \xrightarrow{R^{2}} N \xrightarrow{R^{2}} N \xrightarrow{R^{3}} N \xrightarrow{R^{3}$$

Ib

wherein R<sup>4</sup> is C<sub>1</sub>-6alkyl; or a pharmaceutically acceptable salt thereof or an individual enantiomer or diastereomer thereof.

- 6. (Original) The compound of Claim 1 wherein  $\mathbb{R}^4$  is  $\mathbb{C}_{1\text{--}3}$  alkyl and  $\mathbb{R}^5$  is hydrogen or  $\mathbb{C}_{1\text{--}3}$  alkyl.
- 7. (Original) The compound of Claim 6 wherein  $R^4$  is  $C_{1-3}$ alkyl in the (S) configuration and  $R^5$  is hydrogen.
  - 8. (Original) The compound of Claim 6 wherein  $\mathbb{R}^4$  is methyl and  $\mathbb{R}^5$  is hydrogen.
- 9. (Withdrawn) The compound of Claim 1 wherein R<sup>4</sup> is methyl and R<sup>5</sup> is methyl.

Case No.: 21573YP Page No.: 7

10. (Original) The compound of Claim 1 wherein R<sup>4</sup> is hydrogen and R<sup>5</sup> is hydrogen.

11. (Original) The compound of Claim 1 of the formula Ic:

$$R^{1} \xrightarrow{N} R^{4} R^{5} \xrightarrow{O} R^{2}$$

$$O = S = O$$

$$R^{3}$$

Ic

or a pharmaceutically acceptable salt thereof.

12. (Currently Amended) The compound of Claim 1 wherein  $\mathbb{R}^2$  is selected from the group consisting of:

- (1) phenyl, which is substituted with R<sup>2</sup>a, R<sup>2</sup>b and R<sup>2</sup>c,
- (2) thienyl, which is substituted with R2a, R2b and R2c,
- (3) C<sub>1-8</sub>alkyl, which is unsubstituted or substituted with 1-6 halogen, phenyl or

-NR<sup>10</sup>R<sup>11</sup>, where the phenyl is substituted with R<sup>2a</sup>, R<sup>2b</sup> and R<sup>2c</sup>,

(3) (4) C<sub>3-6</sub>cycloalkyl, which is unsubstituted or substituted with 1-6 halogen, hydroxy or - NR10R11, and

R2a, R2b and R2c are independently selected from the group consisting of:

- (1) hydrogen,
- (2) halogen,
- (3) -C<sub>1</sub>-6alkyl,
- (4) -0-C<sub>1-6</sub>alkyl,
- (4)(5) -CF3,
- <u>(5)(6)</u> -OCF3,
- (6)(7) -OCHF2,

Case No.: 21573YP Page No.: 8

<u>(7)(8)</u> -SCF3,

(8)(9) -SCHF2, and

<u>(9)(10)</u> -NH<sub>2</sub>.

- 13. (Currently Amended) The compound of Claim 12 wherein R<sup>2</sup> is phenyl or thienyl and R<sup>2</sup>a, R<sup>2</sup>b and R<sup>2</sup>c are independently selected from the group consisting of:
  - (1) hydrogen,
  - (2) halogen,
  - (3) -C<sub>1</sub>-6alkyl,
  - (4) -0-C<sub>1-6</sub>alkyl,
  - (4)(5) -CF3,
  - <u>(5)(6)</u> -OCF3,
  - (6)(7) -OCHF<sub>2</sub>,
  - <u>(7)(8)</u> -SCF<sub>3</sub>,
  - (8)(9) -SCHF2, and
  - (9)<del>(10)</del> -NH<sub>2</sub>.
- 14. (Currently Amended) The compound of Claim 13 wherein R<sup>2</sup> is phenyl and R<sup>2</sup>a, R<sup>2</sup>b and R<sup>2</sup>c are independently selected from the group consisting of:
  - (1) hydrogen,
  - (2) fluoro,
  - (3) chloro,
  - (4) bromo,
  - (5) OCH<sub>3</sub>
  - (5)(6) -CF3, and
  - <u>(6)(7)</u> -NH<sub>2</sub>.

15 to 17. (canceled)

Case No.: 21573YP Page No.: 9

18. (Currently Amended) The compound of Claim 1 wherein R<sup>3</sup> is selected from C<sub>1</sub>-6alkyl[[,]] and C<sub>1</sub>-6alkyl-fluoro, C<sub>3</sub>-6cycloalkyl, C<sub>1</sub>-6alkyl-cyclopropyl, -NH(C<sub>1</sub>-6alkyl), -N(C<sub>1</sub>-6alkyl) or azedinyl, which is unsubstituted or substituted with fluoro.

- 19. (Original) The compound of Claim 18 wherein R<sup>3</sup> is -CH<sub>2</sub>CH<sub>3</sub>.
- 20. (Withdrawn) The compound of Claim 18 wherein R<sup>3</sup> is -(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>.
- 21. (Canceled)
- 22. (Currently Amended) A compound which is selected from the group consisting of:
- 2-chloro-3,6-difluoro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{(1S)-1-[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl} benzamide;
- 2-chloro-3,6-difluoro-N-{1-methyl-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
- 2-chloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
- 2,6-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}-benzamide;
- 2-bromo-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
- 2-chloro-6-fluoro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
- 2-amino-6-chloro-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
- 2-fluoro-6-methoxy-N-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
- 2-chloro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
- 2-fluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}-6-(trifluoromethyl)benzamide;
- 2,6-difluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;

Case No.: 21573YP Page No.: 10

```
2-chloro-6-fluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2,6-dichloro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2-chloro-3,6-difluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-
yl]methyl}benzamide;
2-chloro-4-fluoro-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
4-chloro-2-fluoro-N-{[4-(6-methylpyridin-2-vl)-1-(propylsulfonyl)piperidin-4-vl]methyl}benzamide;
2,4-dichloro-N-{[4-(4-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide
2,4-dichloro-N-{[1-(methylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[1-(isopropylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide
2,4-dichloro-N-{[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[1-(cyclopropylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-3-ylpiperidin-4-yl]methyl}benzamide;
2,6-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-3-ylpiperidin-4-yl]methyl}benzamide
2,4-dichloro-N-{[1-(propylsulfonyl)-4-pyridin-4-ylpiperidin-4-yl]methyl}benzamide;
2-chloro-6-fluoro-N-{[1-(propylsulfonyl)-4-pyridin-4-ylpiperidin-4-yl]methyl}benzamide;
2,4-dichloro-N-({1-[(dimethylamino)sulfonyl]-4-pyridin-2-ylpiperidin-4-yl}methyl)benzamide;
4,4,4 trifluoro-3-methyl-N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-
vl]methyl}butanamide;
2-chloro-6-fluoro-N-{[4-(6-morpholin-4-ylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-
yl]methyl}benzamide;
2,4-dichloro-N-{[4-(6-morpholin-4-ylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-
yl]methyl}benzamide;
2,4,5-trifluoro-N-{[4-(6-methoxypyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
2,4-dichloro-5-fluoro-N-{[4-(6-methoxypyridin-2-yl)-1-(propylsulfonyl)piperidin-4-
yl]methyl}benzamide;
N-{[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}cyclohexanecarboxamide;
2-chloro-N-{[1-(cyclopropylsulfonyl)-4-(6-methylpyridin-2-yl)piperidin-4-yl]methyl}-3,6-
difluorobenzamide;
N-{[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}-2,4-difluorobenzamide;
```

N-(sec-butyl)-N'-{[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}urea;

Case No.: 21573YP Page No.: 11

```
N (4-bromophenyl) N' {[1-(propylsulfonyl) 4-pyridin 2-ylpiperidin 4-yl]methyl}urea;
3-fluorobenzyl {[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}carbamate;
2-chlorobenzyl {[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}carbamate;
2,4-dichloro-N-{1-methyl-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2-chloro-3,6-difluoro-N-{1-methyl-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-
vl]ethyl}benzamide;
N-{1-methyl-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}-2-
(trifluoromethoxy)benzamide;
2,4-dichloro-N-{1-methyl-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-
yl]ethyl}benzamide;
2-chloro-3,6-difluoro-N-{1-methyl-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-
yl]ethyl}benzamide;
2,4-dichloro-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
2-chloro-3,6-difluoro-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl} benzamide;
2,4-dichloro-N-{(1S)-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;
2-chloro-3,6-difluoro-N-{(1S)-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-
yl]ethyl}benzamide;
4,4,4-trifluoro-3-methyl-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-
yllethyl}butanamide;
N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}thiophene-3-carboxamide;
N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}cyclopentane-carboxamide;
N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}cyclohexane-carboxamide;
2 ethyl N {(1S) 1 [1 (propylsulfonyl) 4 pyridin 2 ylpiperidin 4 yllethyl} butanamide;
2-methyl-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}butanamide;
```

2,5-dichloro-N-{(1S)-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}thiophene-3-carboxamide;

3,3,3-trifluoro-N-{(1S)-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-

yl]ethyl}propanamide;

4-bromo-N-{(1S)-1-[4-(6-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}thiophene-3-carboxamide;

Case No.: 21573YP Page No.: 12

```
2,5-dichloro-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}thiophene-3-carboxamide;
```

- 4-bromo-N-{(1S)-1-[1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}thiophene-3-carboxamide;
- 2-chloro-*N*-{[1-(propylsulfonyl)-4-pyrimidin-4-ylpiperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-*N*-{[1-(propylsulfonyl)-4-pyrimidin-4-ylpiperidin-4-yl]methyl}benzamide;
- 2-chloro-3,6-difluoro-*N*-{[1-(propylsulfonyl)-4-pyrimidin-4-ylpiperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-5-fluoro-*N*-{[1-(propylsulfonyl)-4-pyrimidin-4-ylpiperidin-4-yl]methyl}benzamide;
- 2-chloro-*N*-{(1*S*)-1-[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl} benzamide;
- 2-chloro-*N*-{(1*S*)-1-[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}-3,6-difluorobenzamide;
- 2-chloro-*N*-{(1*S*)-1-[1-(ethylsulfonyl)-4-(6-methylpyridin-2-yl)piperidin-4-yl]ethyl}-3,6-difluorobenzamide;
- 2,4-dichloro-*N*-{(1*S*)-1-[1-(ethylsulfonyl)-4-(6-methylpyridin-2-yl)piperidin-4-yl]ethyl} benzamide;
- 2,4-dichloro -N-{1-methyl-1-[1-(azetidinesulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
- 2,4-dichloro-N-{1-methyl-1-[1-(3-fluoroazetidinesulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
- 2,4-dichloro-N-{1-methyl-1-[1-(3-fluoroazetidinesulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
- 2,4-dichloro -N-{1-methyl-1-[1-(azetidinesulfonyl)-4-(3-fluoropyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
- 2,4-dichloro-N-{1-methyl-1-[1-(ethylaminosulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
- 2,4-dichloro-N-{[1-[(ethylamino)sulfonyl]-4-(3-fluoropyridin-2-yl)piperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{1-[1-(ethylaminosulfonyl)-4-pyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
- 2,4-dichloro-N-{1-[1-(ethylaminosulfonyl)-4-(3-fluoropyridin-2-ylpiperidin-4-yl]ethyl}benzamide;
- 2,4-dichloro-N-{[4-(3-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-({1-(propylsulfonyl)-4-[6-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methyl)benzamide;
- 2,4-dichloro-N-{[1-[(cyclopropylmethyl)sulfonyl]-4-(3-methylpyridin-2-yl)piperidin-4-yl]methyl}-benzamide;
- 2,4-dichloro-N-({1-(propylsulfonyl)-4-[4-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methyl)benzamide;

Case No.: 21573YP Page No.: 13

```
2,4-dichloro-N-{[4-(3-chloropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
```

- 2,4-dichloro-N-{[4-(3-methoxypyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
- 2-chloro-N-{[4-(3-chloropyridin-2-yl)-1-(ethylsulfonyl)piperidin-4-yl]methyl}-3,6-difluorobenzamide;
- 2,4-dichloro-N-({1-[(cyclopropylmethyl)sulfonyl]-4-pyridin-2-ylpiperidin-4-yl}methyl)benzamide; methyl [(4-{[(2,4-dichlorobenzoyl)amino]methyl}-4-pyridin-2-ylpiperidin-1-yl)sulfonyl]acetate;
- 2,4-dichloro-N-{[1-(ethylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{[1-(propylsulfonyl)-4-pyrazin-2-ylpiperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-(1-{1-[(3-fluoropropyl)sulfonyl]-4-pyridin-2-ylpiperidin-4-yl}ethyl)benzamide;
- 2,4-dichloro-N-({1-[(3-fluoropropyl)sulfonyl]-4-pyridin-2-ylpiperidin-4-yl}methyl)benzamide;
- 2,4-dichloro-N-{[1-[(3-fluoropropyl)sulfonyl]-4-(3-fluoropyridin-2-yl)piperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{[1-[(cyclopropylmethyl)sulfonyl]-4-(3-fluoropyridin-2-yl)piperidin-4-yl]methyl} benzamide:
- 2,4-dichloro-N-{[4-(3-fluoropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
- 2-chloro-3,5-difluoro-N-{[1-[(cyclopropylmethyl)sulfonyl]-4-(3-fluoropyridin-2-yl)piperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-5-fluoro -N-{[1-[(cyclopropylmethyl)sulfonyl]-4-(3-fluoropyridin-2-yl)piperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{1-[4-(3-fluoropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]ethyl}benzamide;
- 2,4-dichloro-N-{[4-(6-trifluoromethylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
- 4-bromo-2-chloro-N-{[1-(ethylsulfonyl)-4-(3-fluoropyridin-2-yl)- piperidin-4-yl]methyl} benzamide; N-(3-fluorobenzyl)-N'-{[1-(propylsulfonyl)-4-(6-trifluoromethylpyridin-2-yl)piperidin-4-yl]methyl} urea;
- 2,4-dichloro-N-{1-[1-(ethylsulfonyl)-4-(3-fluoropyridin-2-yl)- piperidin-4-yl]ethyl}benzamide;
- 2-bromo-4-fluoro-N-{[1-(ethylsulfonyl)-4-(3-fluoropyridin-2-yl)-piperidin-4-yl]methyl}benzamide;
- 2-chloro-3,6-difluoro-N-{[1-(ethylsulfonyl)-4-(3-fluoropyridin-2-yl)- piperidin-4-
- yl]methyl}benzamide;
- 2,4-dichloro-N-{[1-(ethylsulfonyl)-4-(3-trifluoromethylpyridin-2-yl)- piperidin-4-yl]methyl}benzamide;

Case No.: 21573YP Page No.: 14

- 2,4-dichloro-N-({1-[(3-fluoropropyl)sulfonyl]-4-(3-trifluoromethylpyridin-2-ylpiperidin-4-yl}methyl)benzamide;
- 2,4,6-trifluoro-N-{[1-(ethylsulfonyl)-4-(3-trifluoromethylpyridin-2-yl)- piperidin-4-yl]methyl}benzamide;

N (sec-butyl)-N'-{[1-(propylsulfonyl)-4-(6-trifluoromethylpyridin-2-yl)piperidin-4-yl]methyl}urea;

- 2,4-dichloro-N-{[1-(ethylsulfonyl)-4-(3-trifluoromethylpyridin-2-yl)- piperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{1-[4-(3-methylpyridin-2-yl)-1-(propylsulfonyl)piperidin-4-l]ethyl}benzamide;
- N-{[4-(3-bromopyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}-2,4-dichlorobenzamide;
- 2,4-dichloro-N-{[4-(6-fluoropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{[4-(6-chloropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{[4-(6-oxo-1,6-dihydropyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{[4-(3-hydroxypyridin-2-yl)-1-(propylsulfonyl)piperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-{[(2[R,S],4[S,R])-2-methyl-1-(propylsulfonyl)-4-pyridin-2-ylpiperidin-4-yl]methyl}benzamide;
- 2,4-dichloro-N-({1-(ethylsulfonyl)-4-[3-(trifluoromethyl)pyridin-2-yl]piperidin-4-yl}methyl)benzamide;

or a pharmaceutically acceptable salt thereof.

- 23. (Original) A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a compound of Claim 1 or a pharmaceutically acceptable salt thereof.
- 24. (Withdrawn) A method for inhibiting the glycine transporter GlyT1 in a mammal in need thereof which comprises the administration of an effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt thereof.
- 25. (Withdrawn) A method for the manufacture of a medicament for inhibiting the glycine transporter GlyT1 in a mammal in need thereof comprising combining the compound of Claim 1 or a pharmaceutically acceptable salt thereof with a pharmaceutical carrier or diluent.

Case No.: 21573YP Page No.: 15

26. (Withdrawn) A method for treating a neurological and psychiatric disorders associated with glycinergic or glutamatergic neurotransmission dysfunction in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.

27. (Withdrawn) A method for treating schizophrenia in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt thereof.